Special Drug Use Investigation for ZEFIX (Lamivudine) Tablet (HBV Cirrhosis)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

342 participants

Study Classification

OBSERVATIONAL

Study Start Date

2006-06-30

Study Completion Date

2011-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to confirm efficacy and safety when administering lamivudine tablet alone in subjects with hepatitis B virus-induced liver cirrhosis.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Safety and Efficacy of Telbivudine on Liver Cirrhosis in Patients With Chronic Hepatitis B (CHB)

NCT01380951

Liver Cirrhosis Chronic Hepatitis B

UNKNOWN PHASE4

Long-Term Lamivudine Therapy for Chronic Hepatitis B

NCT00120354

Hepatitis B, Chronic

COMPLETED PHASE4

Lamivudine and Adefovir to Treat Chronic Hepatitis B Infection in People With and Without HIV Infection

NCT00023153

HIV Infections Chronic Hepatitis B

COMPLETED PHASE3

Lamivudine for Chronic Hepatitis B

NCT00001457

Chronic Hepatitis B Chronic Hepatitis D Glomerulonephritis +1 more

COMPLETED PHASE2

Adefovir Dipivoxil to Treat Hepatitis B in HIV-Infected Patients

NCT00013702

Hepatitis B HIV Infection

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hepatitis B, Chronic

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

OTHER

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Subjects prescribed lamivudine tablet

Subjects with hepatitis B virus-induced liver cirrhosis prescribed lamivudine tablet during study period

Lamivudine

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Lamivudine

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Subjects with hepatitis B virus-induced liver cirrhosis, in whom lamivudine tablet was administered alone for 6 months or longer, or those in whom lamivudine tablet was expected to be administered alone for 6 months or longer

Exclusion Criteria

* Subjects previously enrolled in Drug Use Investigation or Special Drug Use Investigation of lamivudine tablet
* Subjects with a history of hypersensitivity of the ingredients of lamivudine tablet

Eligible Sex

ALL

Accepts Healthy Volunteers

No